Section Arrow
NBIX.NASDAQ
- Neurocrine Biosciences
Quotes are at least 15-min delayed:2025/02/23 06:34 EST
Last
 120.74
+4.63 (+3.99%)
Day High 
122.37 
Prev. Close
116.11 
1-M High
154.61 
Volume 
1.96M 
Bid
120
Ask
120.76
Day Low
118.57 
Open
121.05 
1-M Low
113 
Market Cap 
11.58B 
Currency USD 
P/E 35.29 
%Yield -- 
10-SMA 120.22 
20-SMA 135.35 
50-SMA 136.18 
52-W High 157.9799 
52-W Low 110.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.29/6.22
Enterprise Value
12.03B
Balance Sheet
Book Value Per Share
25.97
Cash Flow
Cash Flow Yield
0.05
Income Statement
Total Revenue
2.36B
Operating Revenue Per Share
17.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
UPCUniverse Pharmaceuticals Inc0.2003+0.0578+40.56%-- 
TLRYTilray Brands0.9452+0.0775+8.93%-- 
CGCCanopy Growth Corp1.615+0.005+0.31%-- 
TXMDTherapeuticsMD1.291+0.281+27.82%0.39PE
TEVATeva Pharmaceutical Industries Limited16.74-0.26-1.53%-- 
Quotes are at least 15-min delayed:2025/02/23 06:34 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.